Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Ipilimumab

Given by IV (vein)

DRUG

Nivolumab

Given by IV (vein)

DRUG

Ciforadenant

Given by PO

Trial Locations (3)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Duke Cancer Institute, Durham

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER